Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma

Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma